Overview

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

Status:
Withdrawn
Trial end date:
1999-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Analgesics, Opioid
Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone
Criteria
Inclusion Criteria:

Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA
criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence
disorders may also be present. Individuals must be healthy despite drug dependency and have
a history of IV opioid use.

Exclusion Criteria:

Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular
disease) or pregnant female subjects are excluded from study participation.